NovAccess Global Inc.
CIK 1039466fmd_1A854EW3NGZK3KVTZMJNC6CGTCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 1996 to Sep 30, 2024, 71 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 1 | 1 | 1 | 0 | 0 | – | 0 | 0 | 0 |
| Cost of revenue | 1 | 0 | 1 | 0 | 0 | 0 | – | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 |
| Research and development | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 2 | 1 |
| Total operating expenses | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 2 | 1 |
| Operating income | (0) | (0) | (0) | (0) | (1) | (1) | (3) | (1) | (2) | (1) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (0) | (0) | (4) | 2 | (6) | 0 | (0) | (2) | (2) |
| Income before taxes | – | (0) | (0) | – | – | – | – | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (0) | (0) | – | 2 | (7) | (3) | – | – | – |
| Net income | (1) | (0) | (0) | (4) | 2 | (7) | (3) | (2) | (5) | (3) |
| Net income to common shareholders | (1) | (0) | (0) | (4) | 2 | (7) | (3) | (2) | (5) | (3) |